Cellectis says the U.S. patent issued to the company this month will facilitate the development of future development of future T-cell immunotherapy treatments based on CRISPR-Cas . . .
Cellectis’ New Patent Supports CRISPR-Based T-Cell Immunotherapies
CEO Tells GEN Edge “Tech-Agnostic” Company Remains Committed to TALEN-Based Pipeline
T-cell medium for product candidate production. Cellectis says the U.S. patent issued to the company this month will facilitate the development of future T-cell immunotherapy treatments based on CRISPR-Cas. The company’s clinical-phase pipeline consists entirely of treatments that apply its proprietary TALEN® gene editing technology. [Cellectis]
